Nathan Connell on Real-World Evidence: A Safe Switch to New rFVIIa Avoided Over $550K in Costs
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared on LinkedIn:
“New Research: Real-World Evidence on Recombinant Factor VIIa Substitution
I’m excited to share our team’s latest publication in Clinical and Applied Thrombosis/Hemostasis. We conducted a retrospective evaluation of our conversion from eptacog alfa (NovoSeven) to eptacog beta (Sevenfact) to assess both clinical safety and financial impact at Brigham and Women’s Hospital.
Key Findings:
- Safety: The transition to eptacog beta showed no adverse thrombotic events across the patient cohort.
- Efficacy: Effective management was maintained for indications including hemophilia bleeding and peri-procedural management.
- Impact: The medication use evaluation identified an estimated cost avoidance of $554,400 over 12 months.
This study supports the viability of therapeutic interchange for rFVIIa products, offering a pathway for other institutions to maintain high-quality care while optimizing costs.
Read the full open-access article here.”
Title: Real World Experience with use of Coagulation Factor VIIa at an Academic Medical Center
Authors: Alyssa R. George, Katelyn W. Sylvester, Dareen M. Kanaan, Prabashni Reddy, John R. Fanikos, Jean M. Connors, Nathan T. Connell

Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series